KR100819759B1 - Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound - Google Patents
Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound Download PDFInfo
- Publication number
- KR100819759B1 KR100819759B1 KR1020050116596A KR20050116596A KR100819759B1 KR 100819759 B1 KR100819759 B1 KR 100819759B1 KR 1020050116596 A KR1020050116596 A KR 1020050116596A KR 20050116596 A KR20050116596 A KR 20050116596A KR 100819759 B1 KR100819759 B1 KR 100819759B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- azide
- diamino
- acid
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 22
- -1 azide compound Chemical class 0.000 title claims description 9
- 239000002360 explosive Substances 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000001540 azides Chemical class 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 8
- 229940126657 Compound 17 Drugs 0.000 claims description 8
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 229940125797 compound 12 Drugs 0.000 claims description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 229940125773 compound 10 Drugs 0.000 claims description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229940126142 compound 16 Drugs 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 230000000397 acetylating effect Effects 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 15
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 abstract description 6
- 229960002194 oseltamivir phosphate Drugs 0.000 abstract description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract description 2
- 208000002979 Influenza in Birds Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 206010064097 avian influenza Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- IWRUJDWLDJUUNX-UHFFFAOYSA-N CCC(CC)OC(CC(C1)N=[N+]=[N-])C(N)=C1C(OCC)=O Chemical compound CCC(CC)OC(CC(C1)N=[N+]=[N-])C(N)=C1C(OCC)=O IWRUJDWLDJUUNX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- XZXCGRFGEVXWIT-FRRDWIJNSA-N ethyl (1s,5r,6s)-5-pentan-3-yloxy-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate Chemical compound C1C(C(=O)OCC)=C[C@@H](OC(CC)CC)[C@H]2O[C@H]21 XZXCGRFGEVXWIT-FRRDWIJNSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- NMEZJSDUZQOPFE-UHFFFAOYSA-N Cyclohex-1-enecarboxylic acid Chemical class OC(=O)C1=CCCCC1 NMEZJSDUZQOPFE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 뛰어난 항바이러스 효능을 가지며 특히 조류독감 치료에 탁월한 효과를 나타내는 오셀타미비르 인산염의 제조 방법 중 중간체인 화학식 2의 1,2-에폭사이드로부터 화학식 1의 1,2-다이아미노 화합물 또는 이의 약학적으로 허용가능한 부가염을 공업적으로 안정하게 제조하는 다단계 공정을 제공한다.The present invention provides 1,2-diamino compounds of the formula (1) or their compounds from 1,2-epoxides of the formula (2), which are intermediates in the process for preparing oseltamivir phosphate, which have excellent antiviral efficacy and particularly have an excellent effect on avian flu treatment. Provided is a multi-step process for preparing industrially stable pharmaceutically acceptable addition salts.
오셀타미비르 인산염, 아미노알콜, 1,2-에폭사이드, 아지리딘, 1,2-다이아미노 Oseltamivir phosphate, aminoalcohol, 1,2-epoxide, aziridine, 1,2-diamino
Description
본 발명은 바이러스 또는 박테리아의 뉴라민분해효소의 억제제(neuraminidase inhibitor)로서 유용한 오셀타미비르 부가염의 제조 방법 중 중간체인 화학식 2의 1,2-에폭사이드로부터 화학식 1의 1,2-다이아미노 화합물 또는 이의 약학적으로 허용가능한 부가염을 공업적으로 안정하게 제조하는 신규한 다단계 공정에 관한 것이다.The present invention relates to a 1,2-diamino compound of formula (I) from 1,2-epoxide of formula (II), which is an intermediate in the process for preparing oseltamivir addition salt, which is useful as a neuraminidase inhibitor of a virus or bacterium. A novel multistage process for the industrially stable preparation of pharmaceutically acceptable addition salts thereof.
PCT 특허 출원 제 96/26933 호는 바이러스 또는 박테리아의 뉴라민분해효소의 억제제로서 유용한 화합물의 큰 부류 및 이의 제조를 개시하고 있다. 이러한 화합물은 몇 개의 상이한 치환기로 치환될 수 있는 부분 불포화 6원 카보사이클릭 또는 헤테로사이클릭 고리 시스템을 포함한다.PCT Patent Application No. 96/26933 discloses a large class of compounds useful as inhibitors of neuraminidase of viruses or bacteria and their preparation. Such compounds include partially unsaturated 6-membered carbocyclic or heterocyclic ring systems that may be substituted with several different substituents.
PCT 특허 출원 제 98/07685 호는 씨클로헥센 카복실레이트 유도체인 상기 부류의 화합물의 다양한 제조 방법을 개시하고 있다. 쉬킴산(shikimic acid)에서 시작하는 1,2-다이아미노 화합물의 10-단계 제조 방법 또는 퀸산에서 시작하는 12-단계 제조 방법이 롤로프(Rohloff) 등의 문헌[J. Org. Chem., 1998, 63, 4545-4550]에 개시되어 있다. PCT Patent Application No. 98/07685 discloses various methods of preparing compounds of this class which are cyclohexene carboxylate derivatives. 10-step preparation of 1,2-diamino compounds starting with shikimic acid or 12-step preparation starting with quinic acid is described by Rohloff et al. Org. Chem., 1998, 63, 4545-4550.
전체적인 반응식은 하기 반응식 1과 같다.The overall scheme is shown in Scheme 1 below.
삭제delete
상기 10-단계 방법은 중간체인 화합물 6의 1,2-에폭시이드로부터 화합물 10의 1,2-다이아미노 화합물을 합성하는 단계에서 아자이드 시약을 사용하여 화합물 7 및 화합물 9의 단계를 반드시 거쳐야만 한다. 화합물 7로부터 화합물 8을 합성하려면 반드시 무수 조건을 만족시켜야 하는데 이를 위해 농축 과정이 필수적이다. 그러나, 아자이드 화합물은 고농축시 잠재적인 폭발성이 있어 이러한 공정을 수행하기 위해서는 전용 제조 기술 및 고가의 설비가 필요하다. 만일 수분이 소량이라도 존재하면 하기 반응식 2의 화합물 12인 아미노알콜이 생성된다.The 10-step method must pass through the steps of compound 7 and compound 9 using an azide reagent in the synthesis of the 1,2-diamino compound of compound 10 from the 1,2-epoxide of compound 6 , which is an intermediate. . Synthesis of compound 8 from compound 7 must satisfy anhydrous conditions, for which concentration is essential. However, azide compounds are potentially explosive at high concentrations, requiring dedicated manufacturing techniques and expensive equipment to perform these processes. If even a small amount of water is present, aminoalcohol, a compound 12 of Scheme 2, is produced.
삭제delete
이러한 단점을 해결하기 위한 방법으로 화합물 7의 알콜기를 메탄설포닐기로 전환시킨 화합물 13을 거쳐 화합물 8을 합성하는 방법이 김(C. U. Kim) 등의 문헌 [J. Am. Chem. Soc., 1997, 119, 681-690] 에 개시되어 있다.In order to solve this disadvantage, a method of synthesizing compound 8 via compound 13 obtained by converting an alcohol group of compound 7 to a methanesulfonyl group is disclosed in CU Kim et al. Am. Chem. Soc., 1997, 119, 681-690.
그러나, 이 방법에서도 수분이 존재하면 하기 반응식 3과 같이 치환반응에 의한 아지리딘 생성반응과 제거반응에 의한 고리 디엔 화합물 생성 반응이 경쟁적이다. 따라서 원하는 화합물 8 뿐 아니라 제거반응 생성물인 화합물 14와 15가 생성된다. 결국 수율의 저하 및 정제의 어려움이 남아있다.However, even in this method, when water is present, the aziridine production reaction by substitution reaction and the cyclic diene compound production reaction by removal reaction are competitive as in Scheme 3 below. Thus not only the desired compound 8 but also compounds 14 and 15, which are products of removal reactions, are produced. As a result, the yield and the difficulty of purification remain.
삭제delete
또한 미국 특허 제 6,437,171 호는 에폭사이드를 개환하기 위한 알릴아민-마그네슘 브로마이드 에터레이트 및 아지리딘을 개환하기 위한 알릴아민-브뢴스테드를 이용함으로써 1,2-에폭사이드로부터 오셀타미비르 인산염을 제조하는 개선된 방법을 개시하고 있다. 상기 신규한 방법이 아자이드 취급 문제를 해결할지라도, 여전히 에폭사이드로부터 최종 약물 물질로의 전체 수율이 낮다는 문제가 남는다.U.S. Pat.No. 6,437,171 also discloses the preparation of oseltamivir phosphate from 1,2-epoxide by using allylamine-magnesium bromide etherate for ring opening epoxide and allylamine-Bwenstead for ring opening aziridine. An improved method is disclosed. Although the novel method solves the azide handling problem, the problem remains that the overall yield from epoxide to final drug substance is low.
삭제delete
기술 공정의 측면에서, 아자이드 시약 및 아자이드 중간체의 이용을 피하는 것이 바람직하다. 그러나 아자이드 중간체를 거쳐 가는 방법은 중간체인 아자이드 화합물 들의 높은 결정성으로 효과적인 정제가 매우 간편하여, 만일 아자이드 중간체의 폭발성을 제거할 수 있다면 가장 효과적인 합성 경로임에 분명하다. In view of the technical process, it is desirable to avoid the use of azide reagents and azide intermediates. However, the method of going through the azide intermediate is very easy to purify because of the high crystallinity of the intermediate azide compounds, which is obviously the most effective synthetic route if it can eliminate the explosiveness of the azide intermediate.
따라서, 본 발명에서 해결하고자 하는 과제는 아자이드 중간체의 폭발성을 제거할 수 있는 제조 공정을 발견하는 것이다.Therefore, the problem to be solved in the present invention is to find a manufacturing process that can remove the explosiveness of the azide intermediate.
상기 문제점은 하기 명세서 및 첨부된 청구의 범위에 개시되어 있는 바와 같이, 본 발명에 의해 해결되었다.The problem has been solved by the present invention, as disclosed in the following specification and the appended claims.
본 발명에서 해결하고자 하는 과제는 아자이드 중간체의 폭발성을 제거할 수 있는 제조 공정을 제공하는 데 그 목적이 있다.An object of the present invention is to provide a manufacturing process that can remove the explosiveness of the azide intermediate.
이하, 본 발명의 아자이드 중간체의 폭발성을 제거할 수 있는 제조 방법을 상세히 설명한다.Hereinafter, the manufacturing method which can remove the explosive property of the azide intermediate of this invention is demonstrated in detail.
본 발명은 1,2-에폭사이드로부터 1,2-다이아미노 화합물 또는 이의 부가염을 제조하는 개선된 방법에 관한 것으로,The present invention relates to an improved process for preparing 1,2-diamino compounds or addition salts thereof from 1,2-epoxide,
본 발명은 (a) 하기 반응식 4의 화합물 6의 1,2-에폭사이드를 아자이드 시약과 반응시켜, 농축과정을 생략하고, 수분 존재 하에서 중간체인 화합물 12를 합성하고, 다시 중간체인 화합물 16을 거쳐 화합물 17을 형성하는 단계;The present invention (a) by reacting 1,2-epoxide of compound 6 of Scheme 4 with azide reagent, omitting the concentration process, to synthesize compound 12 as an intermediate in the presence of water, and again to obtain compound 16 as an intermediate To form compound 17 ;
(b) 화합물 17을 묽은 산을 사용하여 화합물 18로 전환시키는 단계;(b) converting compound 17 to compound 18 using dilute acid;
(c) 화합물 18을 아자이드 시약과 반응시켜 수분 존재 하에서 화합물 10을 형성하는 단계를 포함하는 것을 특징으로 한다.(c) reacting compound 18 with an azide reagent to form compound 10 in the presence of moisture.
상기 반응식 4에서 R1은 3차-부틸옥시카르보닐기, 트리페닐 메틸기 또는 트리페닐 메틸 유도체기이다. R 1 in Scheme 4 is a tert-butyloxycarbonyl group, triphenyl methyl group or triphenyl methyl derivative group.
상기 단계 (a)는 화합물 6과 아자이드 시약을 반응시키고, 유기용매로 추출하여 별도의 농축과정을 생략하고, 곧바로 아자이드를 환원시켜 화합물 12를 합성한다. 아미노 알콜인 화합물 12를 농축하여 R1치환기를 가진 화합물과 반응시켜 중간체인 화합물 16을 거쳐 화합물 17인 아지리딘을 형성시킨다. 이때 사용하는 R1은 3차-부틸옥시카르보닐기, 트리페닐 메틸기 또는 하기 화학식 3의 트리페닐 메틸 유도체기들이다.Step (a) reacts compound 6 with an azide reagent, extracts them with an organic solvent, omits a separate concentration process, and immediately reduces azide to synthesize compound 12 . Compound 12 , an amino alcohol, is concentrated and reacted with a compound having a R 1 substituent to form compound 17 aziridine via intermediate 16 . In this case, R 1 used is a tert-butyloxycarbonyl group, triphenyl methyl group, or triphenyl methyl derivative groups represented by the following general formula (3).
상기 화학식 3에서 R2, R3, R4는 각각 독립적으로 수소, C1~C10의 알킬기 또는 C1~C10의 알콕시기이다. In the general formula 3 R 2, R 3, R 4 each independently is hydrogen, an alkoxy group of C 1 ~ C 10 alkyl group or a C 1 ~ C 10 of.
상기 단계 (a)는 아자이드 화합물의 농축을 생략하고 수분 존재 하에서 아자이드를 환원시키는 아주 중요한 단계이다. 아자이드 화합물을 추출하는 용매는 보통의 유기용매이며, 물과 섞이지 않으면 된다. Step (a) is a very important step to omit the concentration of the azide compound and to reduce the azide in the presence of moisture. The solvent from which the azide compound is extracted is a common organic solvent and does not have to be mixed with water.
상기 단계 (b)는 화합물 17을 묽은 산을 사용하여 R1을 제거하고 아세틸화시켜 화합물 18로 전환하는 것을 포함한다. 이때 사용하는 묽은 산은 염산, 황산 등의 보통의 무기산과 트리플루오로아세트산 등의 유기산이 가능하다. 묽은 산의 농도는 0.1몰 농도 내지 4몰 농도이며, 바람직하게는 0.5몰 농도 내지 2몰 농도이다.Step (b) comprises converting compound 17 to compound 18 by removing and acetylating R 1 using dilute acid. The dilute acid used at this time may be an ordinary inorganic acid such as hydrochloric acid or sulfuric acid and an organic acid such as trifluoroacetic acid. The concentration of the dilute acid is 0.1 to 4 molar concentrations, preferably 0.5 to 2 molar concentrations.
상기 단계 (c)는 아세틸화된 아지리딘 화합물 18을 아자이드 시약과 반응시키고, 아자이드를 유기용매로 추출하여 별도의 농축과정을 생략하고, 곧바로 아자이드를 환원시켜 화합물 10을 합성한다. In step (c), the acetylated aziridine compound 18 is reacted with an azide reagent, the azide is extracted with an organic solvent, a separate concentration process is omitted, and the azide is immediately reduced to synthesize compound 10 .
본 발명은 추가적으로 하기의 실시예로 예시된다.The invention is further illustrated by the following examples.
실시예1-1 : (3R,4R,5R)-4,5-(N-트리페닐메틸)이미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르의 제조Example 1-1: Preparation of (3R, 4R, 5R) -4,5- (N-triphenylmethyl) imino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester
삭제delete
178ml의 아세토니트릴 중의 (3R,4S,5S)-4,5-에폭시-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르 25.4g(100mmol) 용액에 정제수 76.2ml에 소듐 아자이드 7.8g(120mmol)과 암모늄 클로라이드 6.4g(120mmol)를 녹인 용액을 첨가한다. 용액의 온도를 75℃로 유지하며 6시간 동안 교반하였다. 상온으로 온도를 내리고, 정제수 400ml를 첨가하여 메틸렌 클로라이드 178ml로 추출하였다. 이 용액에 트리페닐포스핀 31.5g(120mmol)을 첨가하여 상온에서 3시간 동안 교반하였다. 실리카겔 75g을 투입하고 1시간 동안 교반 후 여과하여 과량의 트리페닐포스핀과 트리페닐포스핀옥사이드를 제거하고 아미노알콜이 흡착된 실리카겔을 에탄올 254ml에 넣고 1시간 동안 교반하였다. 여과하여 에탄올을 농축하고 메틸렌 클로라이드 50ml와 트리에틸아민 34.4g(340mmol)을 넣는다. 트리페닐메틸 클로라이드 33.5g(120mmol)을 메틸렌 클로라이드 50ml에 녹여 천천히 적가하고 3시간 동안 교반하였다. 아미노기가 보호된 것이 TLC로 확인되면 메탄설포닐 클로라이드13.7g(120mmol)을 천천히 적가하여 2시간 교반한다. 탄산중수소 나트륨 34g을 물 200ml에 녹여 첨가하고 반응 온도를 50℃로 올려 5시간 동안 교반하였다. 층 분리하여 유기 층을 물로 여러 번 세척하고 재결정하여 41g의 고체를 얻었다. Sodium in 76.2 ml of purified water in 25.4 g (100 mmol) solution of (3R, 4S, 5S) -4,5-epoxy-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester in 178 ml of acetonitrile Add a solution of 7.8 g (120 mmol) of azide and 6.4 g (120 mmol) of ammonium chloride. The solution was stirred at 75 ° C. for 6 hours. The temperature was lowered to room temperature, 400 ml of purified water was added, and extracted with 178 ml of methylene chloride. 31.5 g (120 mmol) of triphenylphosphine was added to the solution, followed by stirring at room temperature for 3 hours. 75 g of silica gel was added thereto, stirred for 1 hour, filtered to remove excess triphenylphosphine and triphenylphosphine oxide, and amino alcohol-adsorbed silica gel was added to 254 ml of ethanol and stirred for 1 hour. After filtration, ethanol was concentrated and 50 ml of methylene chloride and 34.4 g (340 mmol) of triethylamine were added thereto. 33.5 g (120 mmol) of triphenylmethyl chloride was dissolved in 50 ml of methylene chloride, slowly added dropwise, and stirred for 3 hours. When TLC confirmed that the amino group was protected, 13.7 g (120 mmol) of methanesulfonyl chloride was slowly added dropwise and stirred for 2 hours. 34 g of sodium bicarbonate was dissolved in 200 ml of water, and the reaction temperature was raised to 50 ° C. and stirred for 5 hours. The layers were separated and the organic layer was washed several times with water and recrystallized to give 41 g of solid.
실시예1-2 : (3R,4R,5R)-4,5-(N-t-부틸옥시카보닐)이미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르의 제조Example 1-2 Preparation of (3R, 4R, 5R) -4,5- (N-t-butyloxycarbonyl) imino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester
삭제delete
50ml의 아세토니트릴 중의 (3R,4S,5S)-4,5-에폭시-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르 25.4g(100mmol) 용액에 정제수 76.2ml에 소듐 아자이드 7.8g(120mmol)과 암모늄 클로라이드 6.4g(120mmol)를 녹인 용액을 첨가한다. 용액의 온도를 75℃로 유지하며 6시간 동안 교반하였다. 상온으로 온도를 내리고, 정제수 400ml를 첨가하여 메틸렌 클로라이드 178ml로 추출하였다. 이 용액에 트리페닐포스핀 31.5g(120mmol)을 첨가하여 상온에서 3시간 동안 교반하였다. 실리카겔 75g을 투입하고 1시간 동안 교반 후 여과하여 과량의 트리페닐포스핀과 트리페닐포스핀옥사이드를 제거하고 아미노알콜이 흡착된 실리카겔을 에탄올 254ml에 넣고 1시간 동안 교반하였다. 여과하여 에탄올을 농축하고 메틸렌 클로라이드 127ml와 트리에틸아민 34.4g(340mmol)을 넣는다. 디-t-부틸 디카보네이트 26.2g(120mmol)을 메틸렌 클로라이드 50ml에 녹여 천천히 적가하고 3시간 동안 교반하였다. 아미노기가 보호된 것이 TLC로 확인되면 메탄설포닐 클로라이드 50g을 천천히 적가하여 2시간 교반한다. 정제수 100ml를 넣어 층 분리한다. 유기 층을 건조하고 트리플루오로아세트산 22.8g(200mmol)를 넣고 30분간 교반한다. 탄산중수소 나트륨 34g을 물 200ml에 녹여 첨가하고 반응 온도를 50℃로 올려 5시간 동안 교반하였다. 층 분리하여 유기 층을 물로 여러 번 세척하고 재결정하여 23g의 오일상의 표지 화합물을 얻었다. Sodium in 76.2 ml of purified water in 25.4 g (100 mmol) solution of (3R, 4S, 5S) -4,5-epoxy-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester in 50 ml of acetonitrile Add a solution of 7.8 g (120 mmol) of azide and 6.4 g (120 mmol) of ammonium chloride. The solution was stirred at 75 ° C. for 6 hours. The temperature was lowered to room temperature, 400 ml of purified water was added, and extracted with 178 ml of methylene chloride. 31.5 g (120 mmol) of triphenylphosphine was added to the solution, followed by stirring at room temperature for 3 hours. 75 g of silica gel was added thereto, stirred for 1 hour, filtered to remove excess triphenylphosphine and triphenylphosphine oxide, and amino alcohol-adsorbed silica gel was added to 254 ml of ethanol and stirred for 1 hour. After filtration, ethanol was concentrated and 127 ml of methylene chloride and 34.4 g (340 mmol) of triethylamine were added thereto. 26.2 g (120 mmol) of di-t-butyl dicarbonate was dissolved in 50 ml of methylene chloride, slowly added dropwise, and stirred for 3 hours. When TLC confirmed that the amino group was protected, 50 g of methanesulfonyl chloride was slowly added dropwise and stirred for 2 hours. Add 100 ml of purified water and separate the layers. Dry the organic layer, add 22.8 g (200 mmol) of trifluoroacetic acid and stir for 30 minutes. 34 g of sodium bicarbonate was dissolved in 200 ml of water, and the reaction temperature was raised to 50 ° C. and stirred for 5 hours. The layers were separated and the organic layer was washed several times with water and recrystallized to obtain 23 g of an oily labeling compound.
실시예2 : (3R,4R,5R)-4,5-(N-아세틸)이미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르의 제조Example 2 Preparation of (3R, 4R, 5R) -4,5- (N-acetyl) imino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester
(3R,4R,5R)-4,5-(N-트리페닐메틸)이미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르24.8g(50mmol)을 메틸렌 클로라이드 250ml에 녹인 용액을 0.5N 염산용액 250ml를 첨가하여 강하게 30분간 교반하였다. 층 분리하여 유기층을 건조하고, 트리에틸아민 6g(60mmol)과 아세트산 무수물 6.5g(60mmol)을 첨가하고 2시간 동안 교반하였다. 정제수 500ml를 첨가하고 층 분리하여 유기 층을 건조하고 농축하여 표지 화합물 15g(수율 98%)을 얻었다.250 ml of methylene chloride (2R, 4R, 5R) -4,5- (N-triphenylmethyl) imino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester The solution dissolved in was added 250 ml of 0.5 N hydrochloric acid solution and stirred vigorously for 30 minutes. The layers were separated and the organic layer was dried. 6 g (60 mmol) of triethylamine and 6.5 g (60 mmol) of acetic anhydride were added and stirred for 2 hours. 500 ml of purified water was added, the layers were separated, and the organic layer was dried and concentrated to give 15 g (yield 98%) of the labeled compound.
실시예3 : (3R,4R,5S)-4-(N-아세틸)아미노-5-아지도-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르의 제조Example 3 Preparation of (3R, 4R, 5S) -4- (N-acetyl) amino-5-azido-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester
(3R,4R,5R)-4,5-(N-아세틸)이미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르 12.5g(42.5mmol)을 디메틸포름아미드 150ml에 녹인 용액에 소듐 아지이드 5g(75mmol)과 암모늄 클로라이드 6g(110mmol)을 첨가한다. 80℃로 5시간 동안 교반하고 정제수 250ml를 첨가한다. 에틸 아세테이트 150ml로 추출하여 유기 층을 건조, 농축하였다. 잔사에 씨클로헥산 150ml를 넣고 5℃에서 재결정하여 흰색 고체의 표지 화합물 13.8g(수율 96%)을 얻었다.150 ml of (3R, 4R, 5R) -4,5- (N-acetyl) imino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester 12.5 g (42.5 mmol) in dimethylformamide To the solution dissolved in 5 g (75 mmol) of sodium azide and 6 g (110 mmol) of ammonium chloride were added. Stir at 80 ° C. for 5 hours and add 250 ml of purified water. Extracted with 150 ml of ethyl acetate, dried and concentrated the organic layer. 150 ml of cyclohexane was added to the residue and recrystallized at 5 ° C. to obtain 13.8 g of a white solid labeled compound (yield 96%).
실시예4 : (3R,4R,5S)-4-(N-아세틸)아미노-5-아미노-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르 인산염(1:1)의 제조Example 4 (3R, 4R, 5S) -4- (N-acetyl) amino-5-amino-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester phosphate (1: 1) Manufacture
(3R,4R,5S)-4-(N-아세틸)아미노-5-아지도-3(1-에틸프로폭시)-1-시클로헥센-1-카복실산 에틸 에스테르 3.3g(9.8mmol)을 에탄올 20ml에 녹인 용액에 란니 니켈(1.1g)을 첨가하고 수소 기체를 16시간 동안 통과시켰다. 반응이 종료되면 여과하여 고체를 제거하고 에탄올 30ml에 85% 인산 1.1g을 녹인 용액을 첨가하였다. 용액을 24시간 방치한 다음 여과하여 표지화합물 3.0g(수율 73%)을 얻었다.(3R, 4R, 5S) -4- (N-acetyl) amino-5-azido-3 (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester 3.3 g (9.8 mmol) in 20 ml of ethanol Lanni nickel (1.1 g) was added to the dissolved solution, and hydrogen gas was passed through for 16 hours. After the reaction was completed, the solid was removed by filtration, and a solution in which 1.1 g of 85% phosphoric acid was dissolved in 30 ml of ethanol was added. The solution was left for 24 hours and then filtered to obtain 3.0 g (yield 73%) of the labeled compound.
mp 203-204 ℃mp 203-204 ° C
본 발명의 오셀타미비르 인산염 또는 중간체 제조 방법은 아자이드 화합물을 무수 조건으로 농축하는 위험한 공정을 아자이드 화합물의 폭발성을 제거한 공정을 이용한 신규한 1,2-다이아미노 화합물의 제조 방법을 제공함으로써 종래의 제조방법에 비해 매우 안정하게 오셀타미비르 인산염 또는 중간체 제조 방법을 제공하는 효과가 있다.The method for preparing oseltamivir phosphate or intermediate of the present invention provides a novel process for preparing 1,2-diamino compounds using a process that removes the explosiveness of azide compounds in a dangerous process of concentrating an azide compound in anhydrous conditions. Compared with the preparation method of the present invention, it is very stable to provide a process for preparing oseltamivir phosphate or intermediate.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050116596A KR100819759B1 (en) | 2005-12-01 | 2005-12-01 | Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050116596A KR100819759B1 (en) | 2005-12-01 | 2005-12-01 | Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070087793A KR20070087793A (en) | 2007-08-29 |
KR100819759B1 true KR100819759B1 (en) | 2008-04-07 |
Family
ID=38613587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050116596A Expired - Fee Related KR100819759B1 (en) | 2005-12-01 | 2005-12-01 | Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100819759B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103304437B (en) * | 2013-05-16 | 2015-07-01 | 广州同隽医药科技有限公司 | Method for synthesizing oseltamivir phosphate without using nitrine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010049507A (en) * | 1999-06-11 | 2001-06-15 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Process for preparing neuraminidase inhibitor ro-64-0796 |
KR100447096B1 (en) | 1995-02-27 | 2005-10-11 | 갈리드사이언스인코오퍼레이티드 | New selective inhibition of viral or bacterial neuraminidase |
-
2005
- 2005-12-01 KR KR1020050116596A patent/KR100819759B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100447096B1 (en) | 1995-02-27 | 2005-10-11 | 갈리드사이언스인코오퍼레이티드 | New selective inhibition of viral or bacterial neuraminidase |
KR20010049507A (en) * | 1999-06-11 | 2001-06-15 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Process for preparing neuraminidase inhibitor ro-64-0796 |
Also Published As
Publication number | Publication date |
---|---|
KR20070087793A (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2397459B1 (en) | Method for producing phenylacetamide compound | |
JP2016540774A (en) | Method for producing adamantane amide | |
CN104447451B (en) | New preparation method of oseltamivir intermediate | |
EP1674446A1 (en) | A method of preparing memantine hydrochloride | |
CN113024489A (en) | Preparation method of oseltamivir synthesis process impurity | |
EA016937B1 (en) | Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydrazinium)propionate esters and use thereof for 3-(2,2,2-trimethylhydrazinium)propionate dihydrate synthesis | |
KR100819759B1 (en) | Method for preparing 1,2-diamino compound or addition salt thereof by using explosive process of azide compound | |
EP3519382B1 (en) | An improved process for the preparation of lacosamide | |
CN110551064A (en) | Preparation method of isavuconazole sulfate and intermediate thereof | |
EP3110791B1 (en) | Process for preparing 2,4-diamino-3-hydroxybutyric acid derivatives | |
EP3067344A1 (en) | Method for preparing lacosamide | |
CN111533656A (en) | Synthesis method of tert-butyl 4-methoxy-3-oxobutyrate | |
RU2804396C1 (en) | Method for the preparation of n-substituted bridging 1,2,4-dioxazolidines | |
CN113651715B (en) | Method for synthesizing coumaroyl dopamine by one-pot method | |
KR102152445B1 (en) | Production method of intermediate compound for synthesizing medicament | |
EP1951654B1 (en) | Improved process for oseltamivir phosphate | |
RU2521593C1 (en) | Mono and difluorosubstituted ethyl (3r,4r,5s)-5-azido-4-acetylamino-3-(1-ethylpropoxy)-cyclohexene-1-carboxylates, method of obtaining and application | |
EP2448916B1 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | |
CN118146111A (en) | Preparation method of oseltamium Wei Suanjia ester | |
CN116813518A (en) | A kind of synthesis method of nematvir chiral intermediate | |
JPH0446175A (en) | Production of 5-hydroxy-3,4-methylenedioxybenzoic acid derivative | |
CN100556906C (en) | A kind of preparation method of important intermediate of protease inhibitor | |
RU2417991C2 (en) | Method of producing 5-amino-6-methyluracil | |
CN118388366A (en) | Novel preparation method of oseltamivir | |
RU2425048C1 (en) | METHOD OF PRODUCING COPPER DIACETATE-DI-ε-CAPROLACTAMATE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20051201 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061111 Patent event code: PE09021S01D |
|
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061214 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20070508 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061214 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20061111 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20070720 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061214 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20061111 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20070820 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20070720 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Patent event date: 20070508 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20080324 Appeal identifier: 2007101008892 Request date: 20070820 |
|
PG1501 | Laying open of application | ||
AMND | Amendment | ||
PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20070913 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20070820 Patent event code: PB09011R01I |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20071001 Patent event code: PE09021S01D |
|
B701 | Decision to grant | ||
PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20080324 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20070920 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080331 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20080331 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20110328 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20120402 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20120402 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130402 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20130402 Start annual number: 6 End annual number: 6 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20150209 |